Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

U.S. charges four with insider trading in NJ drug company

Published 08/31/2017, 02:57 PM
Updated 08/31/2017, 03:00 PM
© Reuters.  U.S. charges four with insider trading in NJ drug company
JAZZ
-

By Jonathan Stempel

(Reuters) - A former accountant at a New Jersey drug company was among four people charged with insider trading on Thursday, after he tipped a close friend that the company would soon be acquired by saying he had a "little bird" that would make its stock "pop."

Evan Kita, 27, of Yardley, Pennsylvania, a former accountant at Celator Pharmaceuticals Inc, pleaded guilty to securities fraud and conspiracy counts, the U.S. Department of Justice said. Two other defendants also entered guilty pleas.

Kita was accused of passing tips in the first half of 2016 about clinical trials for his Ewing Township-based company's leukemia drug, and about Celator's plans to be acquired, ultimately by Dublin-based Jazz Pharmaceuticals Plc (O:JAZZ).

Prosecutors said Kita tipped his friends Daniel Perez, 28, and Richard Yu, 27, and that Richard Yu tipped his father, Chiang Yu, 55.

The resulting trading gains totaled a few hundred thousand dollars, with some money kicked back to Kita, authorities said.

Richard and Chiang Yu, both of Pennington, New Jersey, pleaded guilty to conspiracy charges.

Perez, Kita's next-door neighbor in Yardley, was arrested and also charged with conspiracy, prosecutors said.

The U.S. Securities and Exchange Commission filed related civil charges against the four defendants.

Lawyers for the defendants did not immediately respond to requests for comment.

Court papers said Kita sometimes provided tips through an encrypted smartphone application, including on May 20, 2016, when he told Perez of a deadline for Celator suitors to submit bids.

"Listen," Kita wrote. "I have a little bird[.] And I am told today is a deadline for submitting bids to buy the company[.] Get your ducks in line on your end, idk [I don't know] when it's gonna be announced but it's gonna pop again."

Jazz announced its $1.5 billion takeover of Celator on May 31, 2016, at a 73 percent premium. Celator's stock popped.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.